Compile Data Set for Download or QSAR
Report error Found 413 Enz. Inhib. hit(s) with all data for entry = 9049
TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM372992(US9896418, Compound 64 | US10597366, Compound 64)
Affinity DataEC50:  1nMAssay Description:VEGF: Four hours later, serial dilutions of 10x compound stocks were made in growth medium from 500xDMSO stocks, and 20 uL of those 10x stocks were a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM373015(US9896418, Compound 185 | US10597366, Compound 185)
Affinity DataEC50:  4nMAssay Description:VEGF: Four hours later, serial dilutions of 10x compound stocks were made in growth medium from 500xDMSO stocks, and 20 uL of those 10x stocks were a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM373042(US9896418, Compound 273 | US10597366, Compound 273)
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM372972(US9896418, Compound 11 | US10597366, Compound 11)
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM372966(US9896418, Compound 9 | US10597366, Compound 9)
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM373012(US9896418, Compound 166 | US10597366, Compound 166)
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM373028(US9896418, Compound 233 | US10597366, Compound 233)
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM373041(US9896418, Compound 292 | US10597366, Compound 292)
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM372987(US9896418, Compound 34 | US10597366, Compound 34)
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM373005(US9896418, Compound 159 | US10597366, Compound 159)
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM373004(US9896418, Compound 158 | US10597366, Compound 158)
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM373006(US9896418, Compound 161 | US10597366, Compound 161)
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM437887(US10597366, Compound 160)
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM373024(US9896418, Compound 225 | US10597366, Compound 225)
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM437738(US10597366, Compound 26)
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM372989(US9896418, Compound 55 | US10597366, Compound 55)
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM373008(US9896418, Compound 163 | US10597366, Compound 163)
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent
PDB3D3D Structure (crystal)
TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM373016(US9896418, Compound 186 | US10597366, Compound 186)
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM373015(US9896418, Compound 185 | US10597366, Compound 185)
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM437771(US10597366, Compound 56)
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM373047(US9896418, Compound 309 | US10597366, Compound 309)
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM373043(US9896418, Compound 304 | US10597366, Compound 304)
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM373044(US9896418, Compound 306 | US9896418, Compound 305 ...)
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM373044(US9896418, Compound 306 | US9896418, Compound 305 ...)
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM373031(US9896418, Compound 236 | US10597366, Compound 236)
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM437929(US10597366, Compound 200)
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM437717(US10597366, Compound 6)
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM372964(US9896418, Compound 8 | US10597366, Compound 8)
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM437930(US10597366, Compound 201)
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM438074(US10597366, Compound 329)
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM373021(US9896418, Compound 196 | US10597366, Compound 196)
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM372961(US9896418, Compound 2 | US10597366, Compound 2)
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM372991(US9896418, Compound 63 | US10597366, Compound 63)
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM373019(US9896418, Compound 191 | US10597366, Compound 191)
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM437777(US10597366, Compound 62)
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM437923(US10597366, Compound 194)
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM372960(US9896418, Compound 1 | US10597366, Compound 1)
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM437780(US10597366, Compound 65)
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM372992(US9896418, Compound 64 | US10597366, Compound 64)
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM373017(US9896418, Compound 188 | US10597366, Compound 188)
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM373050(US9896418, Compound 316 | US9896418, Compound 317 ...)
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM437774(US10597366, Compound 59)
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM437773(US10597366, Compound 58)
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent
PDB3D3D Structure (crystal)
TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM438062(US10597366, Compound 321 | US10597366, Compound 31...)
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM372990(US9896418, Compound 60 | US10597366, Compound 60)
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM373004(US9896418, Compound 158 | US10597366, Compound 158)
Affinity DataEC50:  6nMAssay Description:VEGF: Four hours later, serial dilutions of 10x compound stocks were made in growth medium from 500xDMSO stocks, and 20 uL of those 10x stocks were a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM372966(US9896418, Compound 9 | US10597366, Compound 9)
Affinity DataEC50:  6nMAssay Description:VEGF: Four hours later, serial dilutions of 10x compound stocks were made in growth medium from 500xDMSO stocks, and 20 uL of those 10x stocks were a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM373042(US9896418, Compound 273 | US10597366, Compound 273)
Affinity DataEC50:  6.20nMAssay Description:VEGF: Four hours later, serial dilutions of 10x compound stocks were made in growth medium from 500xDMSO stocks, and 20 uL of those 10x stocks were a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM373041(US9896418, Compound 292 | US10597366, Compound 292)
Affinity DataEC50:  6.20nMAssay Description:VEGF: Four hours later, serial dilutions of 10x compound stocks were made in growth medium from 500xDMSO stocks, and 20 uL of those 10x stocks were a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM438089(US10597366, Compound 345 | US10597366, Compound 34...)
Affinity DataIC50: 6.70nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

Displayed 1 to 50 (of 413 total ) | Next | Last >>
Jump to: